Obeticholic acid for the treatment of non|alcoholic steatohepatitis

Obeticholic acid for the treatment of non-alcoholic steatohepatitis

Interpretation: Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The ...

Obeticholic acid for the treatment of non-alcoholic steatohepatitis

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Obeticholic acid for the treatment of nonalcoholic steatohepatitis

Based on 18-month interim findings of the REGENERATE trial, OCA likely improves fibrosis in NASH and therefore may have a beneficial effect ...

Results from a new efficacy and safety analysis of the ...

Obeticholic acid (OCA) is a first-in-class farnesoid X receptor agonist and antifibrotic agent in development for the treatment of ...

Obeticholic acid for the treatment of non-alcoholic steatohepatitis

Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned ...

Obeticholic acid for the treatment of nonalcoholic steatohepatitis

OCA has provided beneficial effects in NASH, including fibrosis improvement. Pruritus and adverse effect on LDL-C should be considered in relation to OCA ...

Obeticholic acid for the treatment of NASH - Nature

There are currently no approved therapies for nonalcoholic steatohepatitis (NASH). In a planned month-18 interim analysis of a multicentre, ...

Resmetirom and Obeticholic Acid for Non-Alcoholic Steatohepatitis ...

Resmetirom is under review as a treatment for NASH with fibrosis, with a Food and Drug Administration (FDA) decision expected in 2023. Page 14 ...

Obeticholic acid for the treatment of nonalcoholic steatohepatitis

Based on 18-month interim findings of the REGENERATE trial, OCA likely improves fibrosis in NASH and therefore may have a beneficial effect in delaying or even ...

Obeticholic acid for the treatment of non-alcoholic steatohepatitis

Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from ...

Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD ...

Our results indicate that OCA might be used as a potential therapeutic drug candidate in NAFLD/NASH management.

Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis

Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis: Interim Results ... Histologic improvement in hepatic fibrosis is shown at 18 ...

Obeticholic acid for the treatment of fatty liver disease—NASH no ...

The quest for effective agents to treat NASH has moved a step forward with the demonstration that treatment with obeticholic acid can ...

Obeticholic acid for the treatment of non-alcoholic steatohepatitis

BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid ...

The effect and safety of obeticholic acid for patients with nonalcoholic...

Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH) is one of the primary causes of chronic liver disease worldwide.

Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis ...

Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: Effectiveness and Value. Institute for Clinical and ...

Obeticholic Acid Impact on Quality of Life in Patients With ...

Patient-reported outcomes (PROs) evaluating HRQoL were assessed in the RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with ...

Obeticholic Acid for the Treatment of Non-alcoholic Steatohepatitis

Now that the FDA has rejected obeticholic acid for NASH, what WAS the evidence supporting its use?

NEW SAFETY AND EFFICACY ANALYSES FROM THE ...

Fibrosis is the best predictor of clinical outcomes in NASH. Obeticholic acid (OCA), a first-in-class farnesoid X receptor agonist, demonstrated efficacy as an ...

Discovery biomarker to optimize obeticholic acid treatment for non ...

The response rate to obeticholic acid (OCA), a potential therapeutic agent for non-alcoholic fatty liver disease, is limited.

Intercept Pharmaceuticals

Biotech company

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.